Search Result

Results for "

IGF-1R

" in MedChemExpress (MCE) Product Catalog:

By Targets:	IGF-1R (40) ADC Antibody (1) Akt (1) Anaplastic lymphoma kinase (ALK) (7) Apoptosis (11) Aurora Kinase (1) Autophagy (3) Bcr-Abl (1) Caspase (1) COX (2) Drug Metabolite (4) EGFR (7) FAK (2) Glucosidase (1) Insulin Receptor (11) Isotope-Labeled Compounds (1) JNK (1) NF-κB (2) PARP (1) PDGFR (3) Pyk2 (1) ROS Kinase (1) Small Interfering RNA (siRNA) (3) Src (2) STAT (1) Trk Receptor (1) TSH Receptor (1) VEGFR (3)
By Research Areas:	Cancer (44) Cardiovascular Disease (2) Endocrinology (21) Infection (1) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (1)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: IGF-1R

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145110

IGF-1R inhibitor-2	IGF-1R	Cancer
IGF-1R inhibitor-2 (example 121) is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor. Downregulation of IGF-1R can reverse the transformed phenotype of tumor cells and potentially render them susceptible to apoptosis ^[1].

HY-156914

IGF-1R/SRC-IN-1	IGF-1R Src	Cancer
IGF-1R/SRC-IN-1 (Compound 3b) is an inhibitor for *IGF-1R* (IC₅₀ is 63 μM) and SRC ^[1].

HY-15609

AZD-3463 ALK/IGF1R inhibitor	IGF-1R Anaplastic lymphoma kinase (ALK) Autophagy Apoptosis	Endocrinology Cancer
AZD-3463 (ALK/IGF1R inhibitor) is an orally active *ALK/IGF1R* inhibitor, with a K_i of 0.75 nM for ALK. AZD3463 induces apoptosis and autophagy in neuroblastoma cells ^[1] .

HY-P99294

Ganitumab AMG 479; Human Anti-IGF1R Recombinant Antibody	IGF-1R	Cancer
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (K_D=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer ^[1].

HY-162506

IGF-1R inhibitor-3	IGF-1R	Cancer
IGF-1R inhibitor-3 (Compound C11) is an allosteric inhibitor for insulin-like growth factor receptor 1 kinase (IGF-1R), with an IC₅₀ of 0.2 μM ^[1].

HY-402309

IGF-1R modulator 1	IGF-1R EGFR Trk Receptor	Neurological Disease
IGF-1R modulator 1 (Example 5) is an *IGF-1R* modulator, with EC₅₀s of 0.29 μM (FGFR1), 0.25 μM (IGF1R), 0.34 μM (TrkA), 0.39 μM (TrkB). IGF-1R modulator 1 can be used for research of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease ^[1].

HY-RS06615

IGF1R Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
IGF1R Human Pre-designed siRNA Set A contains three designed siRNAs for IGF1R gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

IGF1R Human Pre-designed siRNA Set A IGF1R Human Pre-designed siRNA Set A

HY-RS06616

Igf1r Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Igf1r Mouse Pre-designed siRNA Set A contains three designed siRNAs for Igf1r gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Igf1r Mouse Pre-designed siRNA Set A Igf1r Mouse Pre-designed siRNA Set A

HY-RS06617

Igf1r Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Igf1r Rat Pre-designed siRNA Set A contains three designed siRNAs for Igf1r gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Igf1r Rat Pre-designed siRNA Set A Igf1r Rat Pre-designed siRNA Set A

HY-50866B

NVP-AEW541 dihydrochloride AEW541 dihydrochloride	IGF-1R Insulin Receptor Autophagy	Cancer
NVP-AEW541 dihydrochloride (AEW541 dihydrochloride) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC₅₀ value of 0.15 μM. NVP-AEW541 dihydrochloride also inhibits InsR, IC₅₀ with a value of 0.14 μM. NVP-AEW541 dihydrochloride has antitumor activity ^[1].

HY-10524

GSK1904529A 5+ Cited Publications	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC₅₀s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC₅₀>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity ^[1] .

HY-N0908

Ginsenoside Rg5 2 Publications Verification	IGF-1R NF-κB COX	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Ginsenoside Rg5 is the main component of Red ginseng and *IGF-1R* agonist. Ginsenoside Rg5 compets for the binding site of IGF-1R and blocks the binding of *IGF-1* to IGF-1R (IC₅₀ about 90 nM). Ginsenoside Rg5 also inhibits the mRNA expression of COX-2 via suppression of the DNA binding activities of NF-κB p65.

HY-P99672

Istiratumab MM 141; MM-005	IGF-1R EGFR	Cancer
Istiratumab (M-6495) is bispecific monoclonal antibody targeting *IGF-1R* and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers ^[1] .

HY-N0908R

Ginsenoside Rg5 (Standard)	IGF-1R NF-κB COX	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Ginsenoside Rg5 (Standard) is the analytical standard of Ginsenoside Rg5. This product is intended for research and analytical applications. Ginsenoside Rg5 is the main component of Red ginseng and IGF-1R agonist. Ginsenoside Rg5 compets for the binding site of IGF-1R and blocks the binding of IGF-1 to IGF-1R (IC50 about 90 nM). Ginsenoside Rg5 also inhibits the mRNA expression of COX-2 via suppression of the DNA binding activities of NF-κB p65.

HY-18785

Indirubin Derivative E804	IGF-1R	Endocrinology Cancer
Indirubin Derivative E804 is a potent inhibitor of Insulin-like Growth Factor 1 Receptor *(IGF1R), with an IC₅₀* of 0.65 μM for IGF1R.

HY-125102

AZ12253801	IGF-1R	Cancer
AZ12253801 is an ATP-competitive *IGF-1R* tyrosine kinase inhibitor that shows ∼10-fold selectivity over the insulin receptor. AZ12253801 inhibits IGF-1R–driven proliferation in 3T3 mouse fibroblasts (transfected with human IGF-1R) with an IC₅₀ of 17 nmol/L. The IC₅₀ for epidermal growth factor receptor (EGFR)–driven proliferation is 440 nmol/L. Anti-tumor activity.

HY-15494

Picropodophyllin 15+ Cited Publications AXL1717; Picropodophyllotoxin; PPP	IGF-1R Apoptosis	Endocrinology Cancer
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-P99165

Teprotumumab	IGF-1R TSH Receptor	Endocrinology
Teprotumumab is an **IGF-1 receptor (IGF-1R)** blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research ^[1].

HY-116624

MAZ51 3 Publications Verification	VEGFR Apoptosis	Cancer
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ. MAZ51 blocks proliferation and induces apoptosis in a wide variety of tumor cells. Antitumor activity ^[1] .

HY-21291

SU-4313	PDGFR EGFR IGF-1R	Cancer
SU-4313 is a potent protein tyrosine kinases (PTKs) modulator with IC₅₀s of 14.5 μM, 18.8 μM, 11 μM, 16.9 μM, 8.0 μM for PDGFR, FLK-1, EGFR, HER2 Kinase and IGF-1R, respectively. SU-4313 has the potential for modulating tyrosine kinase signal transduction in order to regulate abnormal cell proliferation ^[1].

HY-P99197

Figitumumab CP-751871	IGF-1R	Cancer
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC₅₀ of 1.8 nM ^[1].

HY-14357

BMS 695735	IGF-1R	Cancer
BMS 695735 (compound 10) is an inhibitor of *IGF-1R* with an IC₅₀ value of 0.034 μM. BMS 695735 has anti-tumor activity ^[1].

HY-P99284

Dalotuzumab MK-0646; h7C10	IGF-1R Apoptosis	Cancer
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting *IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2*-mediated tumor cell proliferation, *IGF-1R* autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo ^[1] .

HY-15749

XL228 3 Publications Verification	Aurora Kinase Bcr-Abl IGF-1R Src	Endocrinology Cancer
XL228 is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, *IGF-1R, Src* and Lyn, respectively.

HY-B0794A

AZ7550 hydrochloride	EGFR IGF-1R Drug Metabolite	Endocrinology Cancer
AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of *IGF1R* with an IC₅₀ of 1.6 μM.

HY-B0794B

AZ7550 Mesylate 2 Publications Verification AZ7550 trimesylate salt	EGFR IGF-1R Drug Metabolite	Endocrinology Cancer
AZ7550 Mesylate is an active metabolite of AZD9291 and inhibits the activity of *IGF1R* with an IC₅₀ of 1.6 μM.

HY-B0794

AZ7550	EGFR IGF-1R Drug Metabolite	Endocrinology Cancer
AZ7550 is an active metabolite of AZD9291 and inhibits the activity of *IGF1R* with an IC₅₀ of 1.6 μM.

HY-15494S1

Picropodophyllin-d6 AXL1717-d₆; Picropodophyllotoxin-d₆; PPP-d₆	Isotope-Labeled Compounds IGF-1R Apoptosis	Endocrinology Cancer
Picropodophyllin-d₆ (AXL1717-d₆) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

HY-10262

BMS-536924 3 Publications Verification	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
BMS-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC₅₀s of 100 nM and 73 nM, respectively. BMS-536924 has anti-cancer activity ^[1] .

HY-10253

AG1024 5 Publications Verification Tyrphostin AG 1024	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
AG1024 (Tyrphostin AG 1024) is a reversible, competitive and selective *IGF-1R* inhibitor with an IC₅₀ of 7 μM. AG1024 inhibits phosphorylation of IR (IC₅₀=57 μM). AG1024 induces apoptosis and has anti-cancer activity ^[1] .

HY-P99218

Robatumumab Sch 717454; 19D12	IGF-1R	Cancer
Robatumumab (Sch 717454) is an anti-human *IGF-1R* (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research ^[1] .

HY-N6611

Chimaphilin	IGF-1R	Infection Inflammation/Immunology Cancer
Chimaphilin is an *IGF-1R* inhibitor (IC₅₀: 0.086 μM). Chimaphilin has antifungal, antioxidant and anticancer activities. Chimaphilin inhibits the growth of both drug-sensitive and drug-resistant osteosarcoma cell lines. Chimaphilin can induce cancer cell apoptosis. Chimaphilin is a main component of pyrola ^[1] .

HY-P990084

Veligrotug	IGF-1R	Cancer
Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody ^[1].

HY-50866

NVP-AEW541 5+ Cited Publications AEW541	IGF-1R Insulin Receptor Autophagy	Endocrinology Cancer
NVP-AEW541 (AEW541 ) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC₅₀ value of 0.15 μM. NVP-AEW541 also inhibits InsR, IC₅₀ with a value of 0.14 μM. NVP-AEW541 has antitumor activity ^[1].

HY-13203

NVP-TAE 226 5+ Cited Publications TAE226	FAK Pyk2 IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual FAK and *IGF-1R* inhibitor with IC₅₀s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits Pyk2 and insulin receptor (InsR) with IC₅₀s of 3.5 nM and 44 nM, respectively ^[1] .

HY-15656

Ceritinib Maximum Cited Publications 29 Publications Verification LDK378	Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R	Endocrinology Cancer
Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC₅₀ of 200 pM. Ceritinib (LDK378) also inhibits *IGF-1R, InsR, and STK22D* with IC₅₀ values of 8, 7, and 23 nM, respectively. Ceritinib (LDK378) shows great antitumor potency ^[1] .

HY-15656A

Ceritinib dihydrochloride Maximum Cited Publications 29 Publications Verification LDK378 dihydrochloride	Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R	Endocrinology Cancer
Ceritinib dihydrochloride (LDK378 dihydrochloride) is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor with an IC₅₀ of 200 pM. Ceritinib dihydrochloride (LDK378 dihydrochloride) also inhibits *IGF-1R, InsR, and STK22D* with IC₅₀ values of 8, 7, and 23 nM, respectively. Ceritinib dihydrochloride (LDK378 dihydrochloride) shows great antitumor potency ^[1] .

HY-10252

NVP-ADW742 2 Publications Verification ADW742; GSK 552602A; ADW	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
NVP-ADW742 (ADW742) is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC₅₀ of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC₅₀ of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells ^[1] .

HY-108230

ALK-IN-12	Anaplastic lymphoma kinase (ALK)	Cancer
ALK-IN-12 is a potent and orally active ALK inhibitor with an IC₅₀ of 0.18 nM. ALK-IN-12 also inhibits IGF1R and InsR (IC₅₀=20.3 and 90.6 nM). Antitumor activities ^[1].

HY-15656R

Ceritinib (Standard)	Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R	Endocrinology Cancer
Ceritinib (Standard) is the analytical standard of Ceritinib. This product is intended for research and analytical applications. Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC₅₀ of 200 pM. Ceritinib (LDK378) also inhibits *IGF-1R, InsR, and STK22D* with IC₅₀ values of 8, 7, and 23 nM, respectively. Ceritinib (LDK378) shows great antitumor potency ^[1] .

HY-135680

I-OMe-Tyrphostin AG 538 I-OMe-AG 538	IGF-1R	Metabolic Disease Cancer
I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of *IGF-1R* (insulin-like growth factor-1 receptor tyrosine kinase). I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and is preferentially cytotoxic to nutrient-deprived PANC1 cells. I-OMe-Tyrphostin AG 538 is an ATP-competitive inhibitor of phosphatidylinositol-5-phosphate 4-kinase α (PI5P4Kα), with an IC₅₀ of 1 µM ^[1].

HY-13326

ASP3026 5 Publications Verification	Anaplastic lymphoma kinase (ALK) Apoptosis ROS Kinase Caspase PARP IGF-1R STAT Akt JNK	Cancer
ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC₅₀ value of 3.5 nM. ASP3026 can inhibit the phosphorylation of *IGF-1R, STAT3, AKT* and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research ^[1] .

HY-100349

SU4312	PDGFR VEGFR	Cancer
SU4312 is the racemate of (Z)-SU4312 and (E)-SU4312. (Z)-SU4312 inhibits PDGFR and FLK-1 with IC₅₀s of 19.4 and 0.8 μM, respectively. (E)-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC₅₀s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively ^[1].

HY-100349A

cis-SU4312 (Z)-SU4312	PDGFR VEGFR	Cancer
cis-SU4312 ((Z)-SU4312) inhibits PDGFR and FLK-1 with IC₅₀s of 19.4 and 0.8 μM, respectively. cis-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC₅₀s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively. cis-SU4312 can cross blood brain barrier ^[1].

HY-B0794S

AZ7550-d5	EGFR IGF-1R Drug Metabolite	Others
AZ7550-d₅ is the deuterium labeled AZ7550 (HY-B0794). AZ7550, an active metabolite of Osimtinib (AZD9291; HY-15772), inhibits the activity of IGF1R with an IC50 of 1.6 μM[1][2].

HY-167854

KW-2450 free base	Others	Cancer
KW-2450 Free base is a potent multikinase inhibitor targeting Aurora A and B kinases, demonstrating significant antitumor activity against triple-negative breast cancer (TNBC). KW-2450 Free base effectively reduces cell viability, promotes apoptosis, and inhibits colony formation and mammosphere formation in TNBC cells. KW-2450 Free base significantly suppresses the growth of TNBC xenografts, leading to tetraploid accumulation followed by apoptosis or the survival of octaploid cells. KW-2450 Free base enhances the efficacy of combination therapy with the MEK inhibitor selumetinib, resulting in a synergistic antitumor effect in TNBC models. KW-2450 Free base also acts as an orally bioavailable inhibitor of IGF-1R and IR tyrosine kinases, contributing to its potential antineoplastic activity by inhibiting tumor cell proliferation and inducing apoptosis.

HY-P99712

Lonigutamab hz208F2-4	IGF-1R ADC Antibody	Cancer
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody that can be used for the synthesis of antibody–agent conjugates (ADC) ^[1].

HY-B0025

Voglibose	Glucosidase	Metabolic Disease
Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis ^[1].

HY-10200

BMS-754807 5+ Cited Publications	IGF-1R Insulin Receptor	Endocrinology Cancer
BMS-754807 is a potent and reversible *IGF-1R*/IR inhibitor (IC₅₀=1.8 and 1.7 nM, respectively; K_i=<2 nM for both). BMS-754807 also shows potent activities against Met, RON, TrkA, TrkB, AurA, and AurB with IC₅₀ values of 6, 44, 7, 4, 9, and 25 nM, respectively ^[1].

HY-15357

ALK inhibitor 1 1 Publications Verification	Anaplastic lymphoma kinase (ALK) FAK	Cancer
ALK inhibitor 1 (compound 17) is a potent pyrimidin ALK inhibitor. ALK inhibitor 1 is a potent inhibitor of testis-specific serine/threonine kinase 2 (TSSK2; IC₅₀=31 nM) and focal adhesion kinase (FAK; IC₅₀=2 nM) ^[1].

Cat. No.	Product Name

HY-L034

Anti-Aging Compound Library

4,589 compounds

Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.

MCE Anti-Aging Compound Library contains 4,589 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Cat. No.	Product Name	Target	Research Area

HY-P5438

Srctide	Peptides	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-P5527F

FAM-CSKtide	Peptides	Others
FAM-CSKtide is a biological active peptide. (This is a FAM labeled peptide substrate (Abs/Em = 494/521 nm) for C-terminal Src kinase (Csk) and many other kinases such as Axl, cKit, ERBB4, Fes, Flt3, IGF-1 R, MET, MUSK, PYK2, Ret, TIE2, TrkA, VEGF-R1 and VEGF-R2.)

Cat. No.	Product Name	Target	Research Area

HY-P99294

Ganitumab AMG 479; Human Anti-IGF1R Recombinant Antibody	IGF-1R	Cancer
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (K_D=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer ^[1].

HY-P99165

Teprotumumab	IGF-1R TSH Receptor	Endocrinology
Teprotumumab is an **IGF-1 receptor (IGF-1R)** blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research ^[1].

HY-P99197

Figitumumab CP-751871	IGF-1R	Cancer
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC₅₀ of 1.8 nM ^[1].

HY-P99284

Dalotuzumab MK-0646; h7C10	IGF-1R Apoptosis	Cancer
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting *IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2*-mediated tumor cell proliferation, *IGF-1R* autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo ^[1] .

HY-P99218

Robatumumab Sch 717454; 19D12	IGF-1R	Cancer
Robatumumab (Sch 717454) is an anti-human *IGF-1R* (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research ^[1] .

HY-P990084

Veligrotug	IGF-1R	Cancer
Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody ^[1].

HY-P99712

Lonigutamab hz208F2-4	IGF-1R ADC Antibody	Cancer
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody that can be used for the synthesis of antibody–agent conjugates (ADC) ^[1].

HY-P99189

Cixutumumab IMC-A12; NSC742460	Inhibitory Antibodies	Cancer
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of *IGF-IR*. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer ^[1].

HY-P99672

Istiratumab MM 141; MM-005	IGF-1R EGFR	Cancer
Istiratumab (M-6495) is bispecific monoclonal antibody targeting *IGF-1R* and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers ^[1] .

HY-P990440

*Anti-IGF1R/CD221 Antibody*	Inhibitory Antibodies	Inflammation/Immunology

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99294

Ganitumab AMG 479; Human Anti-IGF1R Recombinant Antibody	Classification of Application Fields Disease Research Fields Cancer	IGF-1R
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (K_D=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer ^[1].

HY-N0908

Ginsenoside Rg5 2 Publications Verification	Panax ginseng C. A. Meyer Cardiovascular Disease Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields Araliaceae Endocrinology	IGF-1R NF-κB COX
Ginsenoside Rg5 is the main component of Red ginseng and *IGF-1R* agonist. Ginsenoside Rg5 compets for the binding site of IGF-1R and blocks the binding of *IGF-1* to IGF-1R (IC₅₀ about 90 nM). Ginsenoside Rg5 also inhibits the mRNA expression of COX-2 via suppression of the DNA binding activities of NF-κB p65.

HY-15494

Picropodophyllin 15+ Cited Publications AXL1717; Picropodophyllotoxin; PPP	Structural Classification Classification of Application Fields Source classification Lignans Dysosma versipellis (Hance) M. Cheng ex Ying Phenylpropanoids Plants Berberidaceae Disease Research Fields Endocrinology	IGF-1R Apoptosis
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-P99197

Figitumumab CP-751871	Classification of Application Fields Disease Research Fields Cancer	IGF-1R
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC₅₀ of 1.8 nM ^[1].

HY-P99284

Dalotuzumab MK-0646; h7C10	Classification of Application Fields Disease Research Fields Cancer	IGF-1R Apoptosis
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting *IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2*-mediated tumor cell proliferation, *IGF-1R* autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo ^[1] .

HY-P99218

Robatumumab Sch 717454; 19D12	Classification of Application Fields Disease Research Fields Cancer	IGF-1R
Robatumumab (Sch 717454) is an anti-human *IGF-1R* (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research ^[1] .

HY-B0025

Voglibose	Structural Classification Microorganisms Classification of Application Fields Source classification Metabolic Disease Disease Research Fields Saccharides	Glucosidase
Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis ^[1].

HY-P99672

Istiratumab MM 141; MM-005	Classification of Application Fields Disease Research Fields Cancer	IGF-1R EGFR
Istiratumab (M-6495) is bispecific monoclonal antibody targeting *IGF-1R* and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers ^[1] .

HY-N0908R

Ginsenoside Rg5 (Standard)	Panax ginseng C. A. Meyer Triterpenes Structural Classification Terpenoids Source classification Plants Araliaceae	IGF-1R NF-κB COX
Ginsenoside Rg5 (Standard) is the analytical standard of Ginsenoside Rg5. This product is intended for research and analytical applications. Ginsenoside Rg5 is the main component of Red ginseng and IGF-1R agonist. Ginsenoside Rg5 compets for the binding site of IGF-1R and blocks the binding of IGF-1 to IGF-1R (IC50 about 90 nM). Ginsenoside Rg5 also inhibits the mRNA expression of COX-2 via suppression of the DNA binding activities of NF-κB p65.

HY-N6611

Chimaphilin	Quinones Structural Classification Passifloraceae Source classification Passiflora incarnata L. Plants Naphthalene Quinones	IGF-1R
Chimaphilin is an *IGF-1R* inhibitor (IC₅₀: 0.086 μM). Chimaphilin has antifungal, antioxidant and anticancer activities. Chimaphilin inhibits the growth of both drug-sensitive and drug-resistant osteosarcoma cell lines. Chimaphilin can induce cancer cell apoptosis. Chimaphilin is a main component of pyrola ^[1] .

HY-P99189

Cixutumumab IMC-A12; NSC742460	Classification of Application Fields Disease Research Fields Cancer	Others
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of *IGF-IR*. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer ^[1].

Species:	Human (6) Mouse (1) Rat (1) Cynomolgus (1)
Tag:	His (9) Avi (2) GST (1)
Source:	HEK293 (7) Sf9 insect cells (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P78458

	IGF-I R Protein, Human (HEK293, His-Avi) CD221; IGF1R; IGF-1R; IGF-I R; IGF-I receptor; IGFIR; IGFR; JTK13; MGC142170; MGC142172; MGC18216	Human	HEK293
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (HEK293, His-Avi) is the recombinant human-derived IGF-I R protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of IGF-I R Protein, Human (HEK293, His-Avi) is 902 a.a., with molecular weight of 110-130 kDa (alpha subunit) & 52-55 kDa (beta subunit), respectively.

HY-P72256

	IGF-I R Protein, Human (His) CD221; CD221 antigen ; IGF 1 receptor; IGF 1R; IGF I receptor; IGF-I receptor; IGF1R; IGF1R_HUMAN; IGFIR; IGFIRC; IGFR; Insulin like growth factor 1 receptor; Insulin like growth factor 1 receptor precursor; Insulin-like growth factor 1 receptor beta chain; Insulin-like growth factor I receptor; JTK13; MGC142170; MGC142172; MGC18216; Soluble IGF1R variant 1; Soluble IGF1R variant 2	Human	E. coli
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (His) is the recombinant human-derived IGF-I R protein, expressed by E. coli , with N-6*His labeled tag. The total length of IGF-I R Protein, Human (His) is 169 a.a., with molecular weight of ~27 kDa.

HY-P78142

	IGF-I R Protein, Human (Biotinylated, HEK293, His-Avi) CD221; IGF1R; IGF-1R; IGF-I R; IGF-I receptor; IGFIR; IGFR; JTK13; MGC142170; MGC142172; MGC18216	Human	HEK293
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived IGF-I R protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of IGF-I R Protein, Human (Biotinylated, HEK293, His-Avi) is 902 a.a., with molecular weight of 110-120 kDa (alpha subunit) & 52-55 kDa (beta subunit), respectively.

HY-P72606

	IGF-I R Protein, Human (HEK293, His) Insulin-like growth factor 1 receptor; IGF-I receptor; IGF1R; CD221	Human	HEK293
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (HEK293, His) is the recombinant human-derived IGF-I R protein, expressed by HEK293 , with C-6*His labeled tag. The total length of IGF-I R Protein, Human (HEK293, His) is 902 a.a., with molecular weight of 100-130 & 54 kDa, respectively.

HY-P74442

	IGF-I R Protein, Human (HEK293, His, solution) Insulin-like growth factor 1 receptor; IGF-I receptor; CD221; IGF1R	Human	HEK293
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (HEK293, His, solution) is the recombinant human-derived IGF-I R protein, expressed by HEK293 , with C-His labeled tag.

HY-P78723

	IGF-I R Protein, Mouse (HEK293, His) IGF1R; IGFR; JTK13; CD221; MGC142170; MGC142172; MGC18216	Mouse	HEK293
	The IGF-I R protein, a receptor tyrosine kinase, mediates insulin-like growth factor 1 (IGF1) actions, with high affinity for IGF1. Upon ligand binding, IGF1R activates, leading to autophosphorylation and tyrosine phosphorylation of substrates, including IRS1/2, Shc, and 14-3-3 proteins. Phosphorylation initiates PI3K-AKT/PKB and Ras-MAPK pathways, regulating proliferation and apoptosis. IGF1R signals through JAK/STAT, activating STAT3, contributing to its transforming activity. It also activates JNK and inhibits JNK activation, forming a hybrid receptor with INSR to bind IGF1. IGF-I R Protein, Mouse (HEK293, His) is the recombinant mouse-derived IGF-I R protein, expressed by HEK293, with C-His labeled tag. The total length of IGF-I R Protein, Mouse (HEK293, His) is 906 a.a., with molecular weight of 110-140 & 50-65 kDa, respectively.

HY-P78724

	IGF-I R Protein, Rat (HEK293, His) IGF1R; IGFR; JTK13; CD221; MGC142170; MGC142172; MGC18216	Rat	HEK293
	Igf1r Protein, a cell surface receptor, is involved in growth regulation and development. Dysregulation of Igf1r Protein has been linked to diseases like cancer and growth disorders. Targeting Igf1r Protein may offer potential therapeutic interventions in these conditions by modulating cell growth, inhibiting tumor progression, and managing growth-related disorders. IGF-I R Protein, Rat (HEK293, His) is the recombinant rat-derived IGF-I R protein, expressed by HEK293 , with C-His labeled tag.

HY-P73137

	IGF-I R Protein, Human (sf9, His-GST) Insulin-like growth factor 1 receptor; IGF-I receptor; CD221; IGF1R	Human	Sf9 insect cells
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (sf9, His-GST) is the recombinant human-derived IGF-I R protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of IGF-I R Protein, Human (sf9, His-GST) is 414 a.a., with molecular weight of ~74.6 kDa.

HY-P78586

	IGF-I R Protein, Cynomolgus (HEK293, His) IGF1R; IGFR; JTK13; CD221; MGC142170; MGC142172; MGC18216	Cynomolgus	HEK293
	The IGF-I R protein is a receptor tyrosine kinase that mediates the effects of insulin-like growth factor 1 (IGF1) and has high affinity for IGF1. Upon ligand binding, IGF1R is activated, leading to autophosphorylation and tyrosine phosphorylation of substrates, including IRS1/2, Shc, and 14-3-3 proteins. IGF-I R Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived IGF-I R protein, expressed by HEK293 , with C-His labeled tag. The total length of IGF-I R Protein, Cynomolgus (HEK293, His) is 878 a.a., with molecular weight (glycosylation form) of 48-58 kDa (β subunit) & 100-115 kDa (α subunit) & 130-150 kDa, respectively.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-15494S1

Picropodophyllin-d6
Picropodophyllin-d₆ (AXL1717-d₆) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

HY-B0794S

AZ7550-d5
AZ7550-d₅ is the deuterium labeled AZ7550 (HY-B0794). AZ7550, an active metabolite of Osimtinib (AZD9291; HY-15772), inhibits the activity of IGF1R with an IC50 of 1.6 μM[1][2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80717

	IGF1 Receptor Antibody IGF1R; Insulin-like growth factor 1 receptor; Insulin-like growth factor I receptor; IGF-I receptor; CD antigen CD221	WB, IHC-P	Human
	IGF1 Receptor Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 155 kDa, targeting to IGF1 Receptor. It can be used for WB,IHC-P assays with tag free, in the background of Human.

HY-P80825

	*Phospho-IGF1 Receptor (Tyr1166) Antibody* IGF1R; Insulin-like growth factor 1 receptor; Insulin-like growth factor I receptor; IGF-I receptor; CD antigen CD221	WB, IP	Human, Mouse, Rat
	Phospho-IGF1 Receptor (Tyr1166) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 155 kDa, targeting to Phospho-IGF1 Receptor (Tyr1166). It can be used for WB,IP assays with tag free, in the background of Human, Mouse, Rat.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

IGF-1R

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products